Literature DB >> 2470618

Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection.

T Hattori1, A Koito, K Takatsuki, H Kido, N Katunuma.   

Abstract

Trypstatin, a new cellular Kunitz-type protease inhibitor purified from rat mast cells, inhibited syncytium formation in human immunodeficiency virus type 1 (HIV-1)-infected CCRF-CEM and uninfected Molt-4 clone 8 at a concentration of 1 microM. Anti-rat tongue mast cell tryptase antibodies reacted with Molt-4 clone 8 cells, as determined by Western blot and by immunofluorescence. In addition, the antibody inhibited syncytium formation. These findings along with homologous sequences with trypstatin and a neutralizing epitope of gp120 of HIV-1 suggest that a tryptase-like cellular enzyme(s) is involved in HIV-1 infection.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2470618     DOI： 10.1016/0014-5793(89)80429-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  36 in total

1.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

Authors:  P Westervelt; H E Gendelman; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.

Authors:  D J Kempf; K C Marsh; D A Paul; M F Knigge; D W Norbeck; W E Kohlbrenner; L Codacovi; S Vasavanonda; P Bryant; X C Wang
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Isolation and characterization of human immunodeficiency virus type 1 variants infectious to brain-derived cells: detection of common point mutations in the V3 region of the env gene of the variants.

Authors:  N S Shimizu; N G Shimizu; Y Takeuchi; H Hoshino
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

4.  A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro.

Authors:  M Levi; M Sällberg; U Rudén; D Herlyn; H Maruyama; H Wigzell; J Marks; B Wahren
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  Computer predictions of functional, topogenic, and antigenic domains in human immunodeficiency virus-2 envelope glycoprotein.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1992-01       Impact factor: 2.332

7.  Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody.

Authors:  S Lu; S D Putney; H L Robinson
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry.

Authors:  R Fernandez-Larsson; K K Srivastava; S Lu; H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

9.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.

Authors:  Y Tani; E Donoghue; S Sharpe; E Boone; H C Lane; S Zolla-Pazner; D I Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.